Market revenue in 2023 | USD 137.1 million |
Market revenue in 2030 | USD 156.0 million |
Growth rate | 1.9% (CAGR from 2023 to 2030) |
Largest segment | Outsourcing |
Fastest growing segment | Outsourcing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | In-house, Outsourcing |
Key market players worldwide | Genpact Ltd, Criterium Inc., Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Labcorp Holdings Inc, FREYR Battery Inc, Pharmexon, Cambridge Design Partnership, Voisin Consulting Life Sciences, Accell, PAREXEL, Promedica International, PharmaLex, NDA Regulatory Service GmbH, QVigilance, BlueReg Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to regulatory affairs market will help companies and investors design strategic landscapes.
Outsourcing was the largest segment with a revenue share of 58.86% in 2023. Horizon Databook has segmented the Singapore regulatory affairs market based on in-house, outsourcing covering the revenue growth of each sub-segment from 2018 to 2030.
Presence of manufacturing units of several multinational pharmaceutical & biotechnology companies, such as Applied Biosystems, Baxter, CIBA Vision, Becton Dickinson, Medtronic, Fisher Scientific, and Siemens Medical Instruments, is anticipated to contribute toward market growth.
In addition, unlike many other Asian countries, Singapore has strong IP rights protection system, which is anticipated to further increase market attractiveness of the country.
Strategic initiatives undertaken by the companies to expand their local presence is also anticipated to have a positive impact on the growth of regulatory services. For instance, in July 2019, Neo Genomics and PPD announced the opening of Neo Genomics clinical trials testing laboratory for oncology in Singapore.
Horizon Databook provides a detailed overview of country-level data and insights on the Singapore regulatory affairs market , including forecasts for subscribers. This country databook contains high-level insights into Singapore regulatory affairs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account